LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases, today announced the successful completion of a US$19 million Series A financing. LQTT is advancing a series of in-licensed compounds discovered and developed by Sanofi …
Trending at Lumira Ventures
BioTheryX Announces Appointments of Three New Members to its Board of Directors
BioTheryX, Inc., a clinical-stage company focused on creating life-saving medicines through targeted protein degradation, today announced the appointments of Nancy Miller-Rich, John A. Hohneker, M.D., and Diantha Duvall to its Board of Directors. “The wealth of biotech leadership and industry knowledge that Nancy, John, …
Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing FGFR3
HAMILTON, ON and BOSTON, July 28, 2021 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) applications …
Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced randomization of …
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 …
American Medical Association (AMA) issued the first ever, unique CPT code for histotripsy of the liver
HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, today announced that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for histotripsy of the liver. Histotripsy of …
Antios Therapeutics and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection
Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios’ proprietary active site polymerase inhibitor …
Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434
Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug uptake across multiple tumor types Enrollment in multi-dosing cohorts continues Fusion also reported preclinical …
Lumira Portfolio Company, G1 Therapeutics, Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated PRESERVE 3, a Phase 2, randomized, open-label study of COSELA™ (trilaciclib) administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy in …
Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. As Senior Vice President, Research
HAMILTON, ON and BOSTON, June 7, 2021: Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Isabelle Dussault, Ph.D. as senior vice president, research. “Isabelle brings deep oncology research experience, including …
Lumira Ventures is proud to be the winner of back-to-back VC Regional Impact Award for Western Canada for 2020 and 2021
Lumira Ventures prides itself on being a VC investor that backs promising early-stage health care and life sciences companies with the potential to dramatically improve patient care. It was with this vision that Lumira co-lead a US$61.5M crossover financing round …
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
TORONTO, ON, June 3, 2021: Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company’s drug candidate EB01 has met a key interim study parameter. The company has now passed the initial …
Fusion Pharmaceuticals, A Lumira Portfolio Company, Enters Into Agreement To Build Radiopharmaceutical Manufacturing Facility
HAMILTON, ON and BOSTON, June 2, 2021: Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing …
Lumira Portfolio Company, enGene, Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial
BOSTON and MONTRÉAL, May 27, 2021: enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first-in-human Phase 1/2 …
Lumira Ventures is pleased to participate in the $92 million Series E financing for BioTheryX
BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving cancer medicines, today announced a $92 million Series E financing led by Farallon Capital Management, with participation from additional new investors Avidity Partners, Deep Track Capital, Janus Henderson Investors, Lumira …